Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction

• Main Authors: Adita Raja, Satoshi Hori, James N Armitage
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2014-01-01
• Series: Indian Journal of Urology
• Subjects: 5-alpha reductase inhibitors; benign prostatic hypertrophy; benign prostatic obstruction; gonadotropin hormone releasing hormone; growth hormone releasing hormone; lower urinary tract symptoms; luteinizing hormone releasing hormone
• Online Access: http://www.indianjurol.com/article.asp?issn=0970-1591;year=2014;volume=30;issue=2;spage=189;epage=193;aulast=Raja

Although the etiology of lower urinary tract symptoms (LUTS) is often multifactorial, a significant proportion of men over the age of 50 suffer from benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia. Prostate, being an androgen responsive organ is dependent on the male sex hormone, testosterone, for growth. Thus, treatment strategies that manipulate the levels of circulating hormones that influence the level of testosterone and/or prostatic growth represent an important potential option for patients suffering with troublesome LUTS due to BPO. Despite this, the only hormonal treatment that is currently used in daily clinical practice is the 5-alpha reductase inhibitor. In this article, we review the current evidence on the use of the 5-alpha reductase inhibitors finasteride and dutasteride. We also discuss new emerging hormonal manipulation strategies for patients with LUTS secondary to BPO.